ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer (NCT03587740)
ATOP TRIAL: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- City of Hope Comprehensive Cancer Center — Duarte, California
- The Stamford Hospital — Stamford, Connecticut
- Dana Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center — Brighton, Massachusetts
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center — Milford, Massachusetts
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital — South Weymouth, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Rex Cancer Center — Raleigh, North Carolina
- Lifespan Cancer Institute — Providence, Rhode Island
- Sarah Cannon Research Institute — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.